Pfizer Stock Screener | Share Price & Fundamental Analysis
PFIZER
Pharmaceuticals
Screen Pfizer share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹4870.50
▼
-16.70 (-0.34%)
Share Price BSE
₹4868.35
▼
-18.95 (-0.39%)
Market Cap
₹22,488.67 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.92
EPS (TTM)
₹136.46
Dividend Yield
3.31%
Debt to Equity
0.01
52W High
₹5889.00
52W Low
₹3913.75
Operating Margin
34.00%
Profit Margin
30.56%
Revenue (TTM)
₹2,745.00
EBITDA
₹1,183.00
Net Income
₹839.00
Total Assets
₹4,911.00
Total Equity
₹4,217.00
Pfizer Share Price History - Stock Screener Chart
Screen PFIZER historical share price movements with interactive charts. Analyze price trends and patterns.
Pfizer Company Profile - Fundamental Screener
Screen Pfizer company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PFIZER shares.
Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives, anti-inflammatories, and respiratory medicines. Pfizer's key focus areas include vaccines, with Prevenar 13 for pneumococcal prevention, and inflammation and immunology treatments for chronic immune system diseases. The company has undergone several mergers, acquisitions, and divestments over the years, including the merger with Wyeth Limited in 2014 and the sale of certain established medicine brands to Mylan Pharmaceuticals in 2022.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Pradip P Shah
ISIN
INE182A01018
Website
https://www.pfizerindia.com
Pfizer Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen PFIZER balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,911 | 4,229 | 4,001 | 3,901 | 3,266 | 4,405 | 3,940 | 3,690 | 3,261 | 2,914 |
| Current Assets | 3,513 | 2,738 | 2,493 | 2,397 | 1,925 | 3,048 | 2,715 | 2,417 | 2,051 | 1,630 |
| Fixed Assets | 724 | 713 | 749 | 869 | 894 | 973 | 886 | 950 | 902 | 895 |
| Liabilities | ||||||||||
| Total Liabilities | 4,911 | 4,229 | 4,001 | 3,901 | 3,266 | 4,405 | 3,940 | 3,690 | 3,261 | 2,914 |
| Current Liabilities | 124 | 87 | 136 | 183 | 99 | 137 | 37 | 52 | 62 | 36 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 4,217 | 3,596 | 3,207 | 2,864 | 2,393 | 3,396 | 3,011 | 2,683 | 2,419 | 2,118 |
| Share Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves & Surplus | 4,172 | 3,550 | 3,162 | 2,819 | 2,347 | 3,350 | 2,966 | 2,637 | 2,373 | 2,072 |
Screen PFIZER income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,745 | 2,454 | 2,374 | 2,526 | 2,674 | 2,320 | 2,336 | 2,249 | 2,083 | 2,067 | 2,103 | 1,921 |
| Expenses | 1,562 | 1,541 | 1,558 | 1,616 | 1,775 | 1,526 | 1,579 | 1,516 | 1,468 | 1,617 | 1,586 | 1,470 |
| EBITDA | 1,183 | 913 | 816 | 910 | 898 | 793 | 757 | 733 | 615 | 450 | 517 | 450 |
| Operating Profit % | 34.00% | 32.00% | 29.00% | 33.00% | 32.00% | 32.00% | 27.00% | 27.00% | 25.00% | 18.00% | 21.00% | 21.00% |
| Depreciation | 60 | 61 | 62 | 106 | 115 | 109 | 103 | 71 | 66 | 63 | 124 | 131 |
| Interest | 10 | 8 | 15 | 13 | 11 | 15 | 11 | 1 | 0 | 1 | 1 | 1 |
| Profit Before Tax | 1,113 | 1,016 | 746 | 824 | 773 | 669 | 643 | 660 | 548 | 517 | 402 | 238 |
| Tax | 282 | 249 | 195 | 200 | 160 | 171 | 133 | 231 | 188 | 180 | 179 | 138 |
| Net Profit | 839 | 768 | 551 | 624 | 613 | 498 | 509 | 429 | 360 | 337 | 223 | 100 |
| EPS | 183.50 | 136.46 | 119.22 | 136.38 | 133.89 | 108.77 | 111.28 | 93.78 | 78.70 | 73.61 | 66.66 | 15.26 |
Pfizer Cash Flow Screener - Liquidity Fundamentals
Screen PFIZER cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 660 | 257 | 356 | 667 | 427 | 323 | 98 | 332 | 329 | 346 |
| Investing Activities | -71 | 54 | -36 | -575 | -469 | 1,530 | 35 | -238 | -250 | -701 |
| Financing Activities | -205 | -235 | -346 | -181 | -1,571 | -164 | -110 | -110 | -83 | -62 |
| Net Cash Flow | 383 | 75 | -26 | -88 | -1,613 | 1,690 | 23 | -17 | -4 | -417 |
Screen PFIZER shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
| FII Holding | 2.60% | 2.39% | 2.18% | 3.33% | 3.22% | 3.54% | 2.75% | 0.00% |
| DII Holding | 17.10% | 17.23% | 17.10% | 15.33% | 15.84% | 16.03% | 16.79% | 14.89% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.08% | 12.02% | 12.34% | 12.90% | 12.55% | 12.15% | 12.12% | 13.70% |
| Other Holding | 4.29% | 4.43% | 4.45% | 4.52% | 4.46% | 4.35% | 4.41% | 7.49% |
| Shareholder Count | 103,480 | 103,222 | 108,261 | 109,214 | 106,098 | 98,824 | 105,015 | 117,194 |
Pfizer Dividend Screener - Share Yield Analysis
Screen PFIZER dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹165.00 | 3.31% |
| 2024-March | ₹35.00 | 0.87% |
| 2023-March | ₹70.00 | 1.67% |
| 2022-March | ₹35.00 | 1.00% |
| 2021-March | ₹35.00 | 0.80% |
| 2020-March | ₹330.00 | 7.29% |
| 2019-March | ₹22.50 | 0.56% |
| 2018-March | ₹20.00 | 0.60% |
| 2017-March | ₹20.00 | 0.92% |
Pfizer Index Membership - Market Screener Classification
Screen PFIZER by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Pfizer Market Events Screener - Corporate Actions
Screen PFIZER market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2022-02-20 | Dividend | ₹ 30.00 /share | 1.61% | |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -4.06% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 0.68% |
| 2025-07-21 | 2025-07-21 | Annual General Meeting | NA | 20.59% |
| 2025-07-09 | 2025-07-09 | Dividend | ₹ 30.00 /share | 32.64% |
| 2025-07-09 | 2025-07-09 | Dividend | ₹ 35.00 /share | 32.64% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 3.80% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -5.60% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -6.42% |
| 2024-08-28 | 2024-08-28 | Annual General Meeting | NA | 0.34% |
| 2024-08-21 | 2024-08-21 | Dividend | ₹ 35.00 /share | 36.12% |
| 2023-08-11 | 2023-08-11 | Dividend | ₹ 35.00 /share | 7.07% |
| 2023-08-11 | 2023-08-11 | Dividend | ₹ 5.00 /share | 7.07% |
| 2022-08-18 | 2022-08-19 | Dividend | ₹ 35.00 /share | -1.09% |
| 2021-08-11 | 2021-08-13 | Dividend | ₹ 30.00 /share | 10.83% |
Pfizer Competitors Screener - Peer Comparison
Screen PFIZER competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Pfizer Company Announcements - News Screener
Screen PFIZER latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-04 | Closure of Trading Window | View |
| 2026-01-03 | Disclosure under Regulation 30A of LODR | View |
| 2025-12-30 | Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-19 | Exclusive Supply And Marketing Agreement With Cipla Limited For Certain Products. | View |
| 2025-11-12 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-03 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-29 | Closure of Trading Window | View |
| 2025-08-13 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025 | View |
| 2025-08-13 | Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025 | View |
| 2025-08-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-08-11 | Launch Of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 20 - Valent (PCV20) | View |
| 2025-08-07 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30 2025 | View |
| 2025-07-22 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-07-21 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-07-02 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-06-30 | Letter To Shareholders Providing The Weblink For Accessing The Annual Report. | View |